IXICO signs its first contract with a new biopharma customer to deploy biosensors in a late stage clinical trial for a psychiatric disorder

Further expansion of IXICO’s biopharma customer base and wearable biosensor technology

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, announces that it has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors (‘wearable biosensors’) in a late stage trial for a psychiatric disorder.

This contract with a new biopharma customer has a value c. £0.75m over a two year term, commencing in November 2017. IXICO will utilise its biosensor capabilities, combined with its artificial intelligence data analytics algorithms, to measure sleep, day time napping, overall daily activity levels and patterns using data collected from c.200 people at multiple time points. Furthermore, the study will allow the exploratory digital measures of patient quality of life to be evaluated alongside standard clinical measures.

By |2017-11-28T10:11:53+00:0021 November 2017|Contracts|